Cost-effectiveness Analysis of Pharmacologic Treatment of Fibromyalgia in Mexico

Ornelas, Héctor Arreola; Buzzo, Alfonso Rosado; Garcı́a, Lourdes; Aguilar, Javier Dorantes; Hernández, Iris Contreras; Quevedo, Joaquín F Mould

doi:10.1016/j.reumae.2011.12.003

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, 12 studies have assessed the cost–utility of different treatments for FM [14,15,16,17,18,19,20,21,22,23,24,25]. Four of them focused on pharmacological treatments, concluding that both pregabalin [15,18,19] and duloxetine [20] would be cost-effective compared to other pharmacological options or placebo. Regarding non-pharmacological interventions, one study evaluated the cost–utility of a cognitive-educational treatment for FM and found that the group discussion component alone was more cost-effective as compared to adding a cognitive component [21].…”

Section: Introductionmentioning

confidence: 99%

Cost–Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)

Pérez‐Aranda

D’Amico

Feliu‐Soler

et al. 2019

JCM

View full text Add to dashboard Cite

Fibromyalgia (FM) is a prevalent, chronic, disabling, pain syndrome that implies high healthcare costs. Economic evaluations of potentially effective treatments for FM are needed. The aim of this study was to analyze the cost–utility of Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment-as-usual (TAU) for patients with FM compared to an adjuvant multicomponent intervention (“FibroQoL”) and to TAU. We performed an economic evaluation alongside a 12 month, randomized, controlled trial; data from 204 (68 per study arm) of the 225 patients (90.1%) were included in the cost–utility analyses, which were conducted both under the government and the public healthcare system perspectives. The main outcome measures were the EuroQol (EQ-5D-5L) for assessing Quality-Adjusted Life Years (QALYs) and improvements in health-related quality of life, and the Client Service Receipt Inventory (CSRI) for estimating direct and indirect costs. Incremental cost-effectiveness ratios (ICERs) were also calculated. Two sensitivity analyses (intention-to-treat, ITT, and per protocol, PPA) were conducted. The results indicated that MBSR achieved a significant reduction in costs compared to the other study arms (p < 0.05 in the completers sample), especially in terms of indirect costs and primary healthcare services. It also produced a significant incremental effect compared to TAU in the ITT sample (ΔQALYs = 0.053, p < 0.05, where QALYs represents quality-adjusted life years). Overall, our findings support the efficiency of MBSR over FibroQoL and TAU specifically within a Spanish public healthcare context.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost–Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study)

Pérez‐Aranda

D’Amico

Feliu‐Soler

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Of the 255 abstracts, based on the inclusion criteria, 56 were selected for further review in full text. In the past 11 years, 55 publications examined economic outcomes associated with pregabalin in FM or neuropathic pain . These 55 publications presented results from 53 studies.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty‐one economic evaluations were found for pregabalin in FM and neuropathic pain . The cost‐effectiveness of pregabalin was assessed with cost‐utility, cost‐effectiveness, and cost‐consequence analyses, most often in the US and Western European countries, but also in Canada, Brazil, Colombia, and Mexico (Table S2).…”

Section: Resultsmentioning

confidence: 99%

“…Five economic models assessed the cost‐effectiveness of pregabalin for pDPN and FM in Mexico . According to three CEAs from the perspective of the Mexican public healthcare system, pregabalin may be a cost‐effective treatment for patients with FM vs. amitriptyline and potentially duloxetine . Two models with a time horizon of 1 year estimated that pregabalin was dominant in FM compared with amitriptyline and cost‐effective compared with duloxetine .…”

Section: Resultsmentioning

confidence: 99%

“…According to three CEAs from the perspective of the Mexican public healthcare system, pregabalin may be a cost‐effective treatment for patients with FM vs. amitriptyline and potentially duloxetine . Two models with a time horizon of 1 year estimated that pregabalin was dominant in FM compared with amitriptyline and cost‐effective compared with duloxetine . Conversely, a decision‐tree model with a 12‐week time horizon estimated that duloxetine dominated pregabalin …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations